deserpidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
derivatives of Rauwolfia alkaloids 810 131-01-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • deserpidine
  • deserpidin
  • raunormin
  • raunormine
  • recanescin
  • recanescine
  • reserpidine
minor descriptor (66-84); on-line search RESERPINE/AA (75-84), RESERPINE (66-74); Index Medicus search RESERPINE/AA (75-84), YOHIMBANS (69-74), RESERPINE (66-68); RN given refers to (3beta,16beta,17alpha,18beta,20alpha)-isomer
  • Molecular weight: 578.66
  • Formula: C32H38N2O8
  • CLOGP: 3.94
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 1
  • TPSA: 108.55
  • ALOGS: -4.72
  • ROTB: 9
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.584 High 0.83
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.953 High 0.83
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 37.239 10^-6 cm/s High 0.83
dh-clint Dog hepatocyte intrinsic clearance 31.405 uL/min/10^6 cells High 0.83
dppb Dog plasma protein binding (% unbound) 2.110 % High 0.83
fcs-ppb Fetal calf serum protein binding (% unbound) 7.470 % High 0.83
herg hERG pIC50 5.092 pIC50 High 0.83
hh-clint Human hepatocyte intrinsic clearance 63.533 uL/min/10^6 cells High 0.83
hlm-clint Human liver microsomal intrinsic clearance 146.555 uL/min/mg protein High 0.83
hppb Human plasma protein binding (% unbound) 2.490 % High 0.83
kinase-safety-class ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK,ZAP70 37
kinase-selectivity-class AXL,GRK2 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.452 High 0.83
mh-clint Mouse hepatocyte intrinsic clearance 163.305 High 0.83
mppb Mouse plasma protein binding (% unbound) 2.960 High 0.83
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 5.943 High 0.83
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 5.730 % High 0.83
rh-clint Rat hepatocyte intrinsic clearance 191.867 uL/min/10^6 cells High 0.83
rh-fuinc Rat hepatocyte fraction unbound in incubation 21.560 % High 0.83
rppb Rat plasma protein binding (% unbound) 2.140 % High 0.83
solubility-dd Solubility at pH 7.4 in DMSO 4.819 uM High 0.83

Approvals:

DateAgencyCompanyOrphan
April 19, 1957 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02AA05 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Rauwolfia alkaloids
ATC C02LA03 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Rauwolfia alkaloids and diuretics in combination
FDA EPC N0000175640 Catecholamine-depleting Sympatholytic
FDA PE N0000175650 Decreased Sympathetic Activity
CHEBI has role CHEBI:35674 antihypertensive agent

Related Drugs by ATC class:

C02AA Rauwolfia alkaloids 4 drugs
bietaserpinemethoserpidinerescinnaminereserpine
C02LA Rauwolfia alkaloids and diuretics in combination 5 drugs
bietaserpinemethoserpidinerescinnaminereserpinesyrosingopine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Fluid volume disorder contraindication 1860003
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Cirrhosis of liver contraindication 19943007 DOID:5082
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Hypertriglyceridemia contraindication 302870006
Azotemia contraindication 445009001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.2 acidic
pKa2 6.78 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Synaptic vesicular amine transporter Transporter INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4018732 VUID
N0000147037 NUI
D08194 KEGG_DRUG
62174 RXNORM
4018732 VANDF
C0175158 UMLSCUI
CHEBI:27478 CHEBI
CHEMBL1200515 ChEMBL_ID
DB01089 DRUGBANK_ID
C100104 MESH_SUPPLEMENTAL_RECORD_UI
7064 IUPHAR_LIGAND_ID
656 INN_ID
9016E3VB47 UNII
8550 PUBCHEM_CID
4544 MMSL
d03563 MMSL
000642 NDDF
26503009 SNOMEDCT_US
387144003 SNOMEDCT_US
9016E3VB47 INXIGHT DRUGS

Pharmaceutical products:

None